Dr. Moore on Safety Profile of Mirvetuximab Soravtansine in Ovarian Cancer

Dr. O’Malley on the Safety Profile of Mirvetuximab in Ovarian CancerПодробнее

Mirvetuximab Soravtansine Remains Well Tolerated in Platinum-Resistant Ovarian CancerПодробнее

Dr. Moore on Early-Phase Data With Mirvetuximab Soravtansine in Ovarian CancerПодробнее

Dr. English on Mirvetuximab Soravtansine in Ovarian CancerПодробнее

Dr. Moore on Anticipated Impact of the MIRASOL Trial in Platinum-Resistant Ovarian CancerПодробнее

An Overview of a Study Exploring Mirvetuximab Soravtansine in Ovarian CancerПодробнее

Dr. Moore on the Role of Mirvetuximab Soravtansine in Ovarian CancerПодробнее

Dr. Gilbert on the Safety Profile of Mirvetuximab Soravtansine/Bevacizumab in Ovarian CancerПодробнее

Dr. Moore on Benefit of Mirvetuximab Soravtansine in Patients With Ovarian CancerПодробнее

Results for Combination Bevacizumab Plus Mirvetuximab Soravtansine in Ovarian CancerПодробнее

Dr. O’Malley on the Utility of Mirvetuximab in Ovarian CancerПодробнее

#ESMO19: FORWARD I (GOG 3011) Study for Platinum-Resistant Ovarian CancerПодробнее

FORWARD I: mirvetuximab soravtansine vs chemo in platinum-resistant ovarian cancerПодробнее

Dr. Moore on Results of the FORWARD I/GOG 3011 Trial in Ovarian CancerПодробнее

Dr. Moore on the NOVA Trial for Ovarian CancerПодробнее

Dr. Matulonis Discusses Mirvetuximab Soravtansine Plus Pembrolizumab in Ovarian CancerПодробнее

Mirvetuximab Soravtansine Combination Improves Responses in Platinum-Agnostic Ovarian CancerПодробнее

Dr. Moore on the Prevalence of Ovarian CancerПодробнее

Mirvetuximab Soravtansine: The SORAYA & MIRASOL Studies. The future of Targeting FRαПодробнее